Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Heterogeneity of treatment effect
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Approaches to treatment

Heterogeneity of treatment effect

4 evidence topics · 3 sources

Genetic modifiers of anti-VEGF response

“Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.” (opens the source at this quote in a new tab)
“For both rs800292 and rs6677604, carriage of the A allele was protective and decreased the nAMD risk.” (opens the source at this quote in a new tab)

Knowledge-guided individualization

“Unraveling the association between AMD genetics and response to therapy could pave the way for personalized AMD treatment, with genetic variants serving as predictors of its outcome, treatment regimen, and dosage mode.” (opens the source at this quote in a new tab)

Lesion and dosing-driven heterogeneity across agents

“aflibercept 2 mg, aflibercept 8 mg, bevacizumab 1.25 mg (off‐label or on‐label), brolucizumab 6 mg, faricimab 6 mg, ranibizumab 0.5 mg, and the corresponding biosimilars.” (opens the source at this quote in a new tab)
“One main underlying factor influencing visual outcomes is the average number of injections over time,” (opens the source at this quote in a new tab)

Sex-related heterogeneity in incidence and burden

“The incidence of nAMD in women was almost two-fold greater compared to males at the same age.” (opens the source at this quote in a new tab)